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Introduction: Ewing’s sarcoma (ES) is the second most common bone tumor in children.
Survival has not improved over the last decade and once pulmonary metastatic disease
is present, survival is dismal. Mesenchymal stromal cell (MSC) therapy has shown poten-
tial benefit for Kaposi’s sarcoma; however, the role of progenitor cell therapies for cancer
remains controversial. MSC treatment of ES or pulmonary metastatic disease has not been
demonstrated. We have developed an orthotopic xenograft model of ES in which animals
develop spontaneous pulmonary metastases. Within this model, we demonstrate the use
of MSCs to target ES lung metastasis.
Materials and Methods: Human ES cells were transfected with luciferase and injected
into the rib of nude mice. Development of pulmonary metastases was confirmed by imag-
ing. After flow cytometry based characterization, MSCs were injected into the tail vein of
nude mice with established local ES tumor or pulmonary metastasis. Mice were treated
with intravenous MSCs weekly followed by bioluminescent imaging.
Results: The intravenous injection of MSCs in an ES model decreases the volume of pul-
monary metastatic lesions; however, no effect on primary chest wall tumor size is observed.
Thus verifying the MSC preferential homing to the lung. MSCs are found to “home to” the
pulmonary parenchyma and remain engrafted up to 5 days after delivery.
Discussion: MSC treatment of ES slows growth of pulmonary metastasis. MSCs have
more affinity for pulmonary metastasis and can effect a greater decrease in tumor growth
in the lungs compared to the primary tumor site.
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INTRODUCTION
Ewing’s sarcoma (ES) is a primitive neuroectodermal tumor and
is the second most common bone tumor in children and young
adults (ages 5–30) (1). Current multimodal therapy for localized
disease consisting of tumor resection with/without radiation and
concordant multidrug chemotherapy, still fails 20–40% of the time
resulting in metastatic disease. Metastatic ES continues to have
a dismal prognosis with fewer than 20% of patients surviving
at 5 years. Despite multiple attempts to develop novel therapies
including total body irradiation with autologous bone marrow
transplantation (2) and induction with highly toxic chemothera-
peutic regimens (3), no improvement in the mortality associated
with metastatic disease (approaching 90%) has been observed for
over 40 years (4).
A growing amount of preclinical research has been completed
investigating the potential role of bone marrow derived mes-
enchymal stromal cell (MSC) therapy for the treatment multi-
ple forms of cancer. By definition, MSCs are multipotent and
have the capacity for self renewal (5) making them ideal can-
didates for novel therapeutic strategies. The intravenous injec-
tion of MSCs has been associated with migration toward the
site of tumor inflammation with increased levels of engraftment
(6). In non-tumorigenic animal models, MSCs have also been
found to preferentially migrate to the lung after intravenous injec-
tion (7). Pulmonary passage is a major obstacle for intravenous
stem cell delivery: the pulmonary first-pass effect. The observed
increased engraftment in the lungs makes MSCs attractive as vehi-
cles for the delivery of anti tumorigenic proteins to pulmonary
sites.
Preliminary research using an ES model has shown the success-
ful intravenous delivery of MSCs transfected with a gene for the
anti tumorigenic protein interleukin 12 (IL-12). The transplanted
MSCs were found to engraft at tumor sites and increase local IL
12 production leading to a decrease in tumor burden (8). While
such initial studies have shown great potential, limited research
has been completed to investigate the role of progenitor cell ther-
apies for ES. There are no studies currently published to evaluate
the potential role of MSCs in ES lung metastasis.
The design of future studies to investigate the potential use of
MSC therapy for ES requires the development of tested animal
models. Therefore, we evaluated the effect of intravenous MSC
injection on both primary and metastatic tumor sites using a novel
ES model (9). We hypothesize that the transplanted MSCs will
engraft in the lung and decrease pulmonary metastasis.
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EXPERIMENTAL DESIGN AND METHODS
IN VIVO
All procedures were approved by the institutional animal care and
use committee and were consistent with the National Institutes
of Health’s Guide for the Care and Use of 13 Laboratory Animals
(HSC-AWC-07-031).
TC71 human ES cells transfected with a luciferase reporter were
injected in the rib of nude female mice. As previously described,
our model is associated with a 60% incidence of chest wall tumors
alone, 30% incidence of pulmonary metastasis alone, and 10%
incidence of synchronous chest wall and pulmonary metastatic
tumors (9). Next, quantum dot labeled rat MSCs were injected via
the tail vein at 1, 2, and 3 weeks after ES implantation for a total
of three doses. Then, the mice were harvested at 1, 2, and 3 weeks
after completion of the MSC injections. Chest wall and pulmonary
metastasis tumor burden as well as quantum dot labeled MSC
location and burden were then measured.
ORTHOTOPIC CHEST WALL MODEL
The ES model has been described in a previous publication (9).
Briefly, approximately 8-week old, 25 g, female athymic nude
(nu/nu) mice were obtained from the National Cancer Insti-
tute (Frederick, MD, USA). A total of 500,000 TC71 cells were
suspended in 20µL of phosphate buffered saline (PBS). After
induction of anesthesia, an incision was made in the posterior-
lateral chest wall and the cells were injected into the periosteum of
the lower rib using a 27 gage needle; the wound was then closed
with sutures. All mice were monitored for full recovery after anes-
thesia. Mice were examined daily and tumor size was measured
three times/week using calipers. All animals underwent com-
plete necropsy. For subsequent quantification of tumor volume,
bioluminescent imaging was used.
EWING’S SARCOMA CELL CULTURE AND TRANSFECTION
TC71 human ES cells were cultured as previously described (10,
11) to create luciferase-labeled tumor cells, the full-length fire-
fly luciferase gene was spliced into the MigR1 expression vector
and viral particles generated as previously described (12). TC71
cells were transduced on two consecutive days with infectious
supernatant and then incubated for 48 h to allow for expression of
incorporated retrovirus. Expression of EGFP, present as the sec-
ond cistron in the expression cassette and translated under the
direction of an internal ribosomal entry sequence, was confirmed
via direct fluorescent microscopy. Transduced cells were purified
via flow cytometry to select EGFP-expressing cells and luciferase
expression was confirmed by visible light emission upon addition
of luciferin.
ISOLATION, CHARACTERIZATION, AND LABELING OF RAT
MESENCHYMAL STEM CELLS
Mesenchymal stromal cells were isolated from the bone marrow of
Sprague-Dawley rats and expanded in MAPC media as previously
described (13). Flow cytometric immunophenotyping was used
to ensure the MSCs were CD11b−, CD45−, CD29+, CD49e+,
CD73+, CD90+, CD105+, and Stro 14 1+. MSCs were labeled
with the Qtracker 655 Cell Labeling Kit (Invitrogen, Carlsbad,
CA, USA) per the manufacturer’s suggested protocol. Cell-labeling
efficiency was >90% as confirmed by flow cytometry. Passage 3
cells were used for all experiments. For imaging in the mouse, the
Qtracker signal was labeled red.
The rationale for using 1× 106 MSCs is based on previous expe-
rience with the use of MSCs in a non-tumor model. These amount
of MSC cells were adequate to detect in all organs. Because it is
technically easier to isolate rat MSCs, compared to mice, rat MSCs
are used in this study.
DELIVERY OF MSCs
Mesenchymal stromal cells were removed from culture plates with
1X trypsin and washed with PBS. Next, the cells were suspended
in PBS at a concentration of 1 million MSCs per milliliter of PBS
and placed on ice until injection. After induction of anesthesia,
the tail vein was cleansed with betadine and 1 million MSCs were
injected. MSC injections were completed 1, 2, and 3 weeks after
ES implantation. There were 15 mice in each group; one central
group injected with PBS; one central group injected with lung and
epithelial cells (CRL2300); and one treatment group.
BIOLUMINESCENT IMAGING
After the injection of cells, the mice were imaged at different
time points using an in vivo. IVIS 100 bioluminescence/optical
imaging system (Xenogen, Alameda, CA, USA). d-Luciferin
(Xenogen,Alameda, CA, USA) dissolved in PBS was injected intra-
peritoneally at a dose of 150 mg/kg 10 min before measuring light
emission. General anesthesia was induced with 5% isoflurane and
five continued during the procedure. After acquiring photographic
images of each mouse, luminescent images were acquired with var-
ious (1–60 s) exposure times. The resulting grayscale photographic
and pseudocolor luminescent images were automatically superim-
posed by the IVIS Living Image (Xenogen) software to facilitate
matching the observed luciferase signal with its location on the
mouse. Regions of interest (ROI) were manually drawn around
the bodies of the mice to assess signal intensity emitted. Lumines-
cent signal was expressed as photons per second emitted within
the given ROI. Tumor bioluminescence in mice linearly correlated
with the tumor volume (14). Changes in tumor volumes were
calculated by the ROI. Quantification used to calculate p values
include Fisher exact test.
RESULTS
HOMING AND ENGRAFTMENT OF MSCs
After orthotopic Ewing’s chest wall tumors were established, MSCs
were isolated, labeled, and delivered intravenously. Unexpectedly,
the “naked” MSCs caused reduction in size of primary tumors and
more so, lung metastasis.
First, we show MSCs exclusively home to the site of the tumor.
Figure 1 displays the primary chest wall tumor at 1, 2, and 3 weeks
after three weekly consecutive MSC treatments. MSCs (red hues
label the MSCs) home to the primary tumor site (blue hues indi-
cate ES tumor) almost exclusively. At 1 week, 10 mice are seen with
large chest wall tumors. At 2 weeks, the red hues show continued
engraftment of the MSCs after two weekly injections in five mice.
Also at 2 weeks, decreased tumor size can be seen in the chest wall
tumor. At 3 weeks, chest wall tumor growth is stable.
Figure 2 displays the lung metastasis pattern of tumor and
MSC engraftment. These mice developed spontaneous bilateral
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FIGURE 1 | MSC therapy in primary Ewing’s sarcoma. The red color is
labeled MSCs and the blue hues are labeled Ewing’s sarcoma TC71 cells.
(A) Mice after the orthotopic implantation of human Ewing’s sarcoma
cells into the rib to form chest wall tumors. (B) Mice 2 weeks after
completion of two doses of intravenous mesenchymal stem cells
(MSCs). The top panel shows a decrease in size of the primary chest wall
tumors. The bottom panel indicates that the MSCs preferentially
migrated to and engrafted at the site of chest wall tumors. (C) Mice
3 weeks after completion of three doses of intravenous MSCs where
tumor starts to re-grow. The top panel shows no difference in primary
tumor size when compared to control animals. The bottom panel
indicates that the MSCs preferentially migrated to and engrafted at the
site of chest wall tumors. Luciferase reporter from Ewing’s sarcoma cells
show as intensity gradient from low to high cell load indicated by blue to
red. Quantity of quantum dot labeled MSCs indicated by intensity of red
color in bottom panel.
FIGURE 2 | MSC inhibition of metastatic Ewing’s sarcoma. (A) Mice
after the periosteal rib implantation of luciferase-labeled Ewing’s sarcoma
cells (TC-T1) showing spontaneous bilateral pulmonary metastasis.
(B) A decrease in luciferase-labeled Ewing’s sarcoma cells is observed up
to 3 weeks after completion of intravenous MSC therapy as indicated by
decreased blue signal. In addition, the injected MSCs were found to
preferentially migrate to and engraft at the tumor sites as indicated by red
intensity. (C) Quantification of the signal from the luciferase reporter
shows a significant decrease in tumor burden 2 and 3 weeks after the
completion of MSC therapy.
lung metastasis. In Figure 2B, 3 weeks after MSC therapy, lung
metastasis in the three mice pictured, has significantly decreased
in size. Again as in the primary tumor, overlap of the red hues
(MSCs) and blue hues (lung metastasis) demonstrate successful
MSC engraftment. Slowing of lung metastatic growth in all six
mice is quantified in Figure 2C.
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We then wanted to identify the exact location microscopically of
the MSCs in relationship to the primary tumor cells and MSCS in
each organ. Organ explants from mice given MSCs were compared
FIGURE 3 | MSCs home preferentially to the lung. Tracking of the
injected MSCs was completed by labeling the cells with quantum dots
followed fluorescent imaging 6 h after injection. MSC injection was done
after established chest wall tumors were 1 cm in size. The majority of MSCs
remain within the lung parenchyma with very few found within the primary
chest wall tumors. It is important to note that the MSCs remain within the
lung in groups with or without pulmonary metastasis. This tracking
experiment was repeated with lung epithelial cells (CRL2300) with similar
results (cells remained sequestered in lung parenchyma with few found in
primary chest wall tumors) (CWT, chest wall tumor; LM, lung metastasis).
to mice in which lung epithelial cells (CRL2300) were delivered as
controls. Figure 3 shows MSCs (green) distributed in lung with
and without metastasis (f–i) with no MSCs seen in normal heart,
kidney, liver, or spleen, at day 1 after treatment. Control animals
were treated with labeled lung epithelial cells (CRL2300) (b–e). In
contrast to the MSCs, few lung epithelial cells are seen in the lung
without (b, d, e) or with (c) lung metastasis after intravenous (iv)
delivery.
In animals with lung metastasis, after MSC delivery (f), MSCs
infiltrate the lung parenchyma surrounding the tumor. No lung
epithelial cells (d, e) and some MSCs (h, i) are seen infiltrating
the primary tumors (red). Microscopically, the MSCs home to the
lung metastasis more than the primary tumor.
MSCs REMAIN ENGRAFTED IN THE LUNG AND DECREASE THE
INCIDENCE OF PULMONARY METASTASIS
We then evaluated the longevity of MSC engraftment. Figure 4
shows animals at 3 and 5 days after iv delivery of MSCs. In Figure 4,
labeled MSCs are seen in lung with and without lung metastases up
to 5 days after injection. Few to no MSCs are seen in the primary
tumor (c, d). Lung epithelial cells (CRL2300) were also injected
as a non-specific cell line control and were also found to remain
within the lungs 5 days after injection, but no tumor reduction was
seen after injection of lung epithelial cells. Engraftment of MSCs
are seen evenly distributed in lung without (c) and with (d) lung
metastasis at day 3 and day 5.
MSCs INHIBIT PULMONARY METASTASIS IN ES
Mesenchymal stromal cell therapy resulted in a decrease in the
volume of lung metastasis after 3 weeks of treatment. Signifi-
cantly, less tumor is seen in the lung metastasis of the mice
treated with MSC therapy compared to those treated with con-
trol lung epithelial cells (Figure 5). Lung epithelial cells did not
FIGURE 4 | Infrared whole mount images of mouse organs. Red color
indicates labeled tumor cells. MSCs are labeled green. Tumor= chest wall
tumors from the rib injection site, which are completely red with no
engrafted MSCs. Organs from two different mice on day 3 and day 5 after
injection, are labeled. A-day 3 after MSC delivery. Red lung metastasis is
seen in the top right image. Green MSCs are seen infiltrating the lung. The
lung on the left does not have metastasis. (B) Day 5 – MSCs are seen
engrafted in the lung with small tumors on the top left and no tumor on
the top right. Red chest wall primary tumors do not show engraftment. We
conclude from this that MSCs home to and engraft in lung but not primary
tumor. Magnification of organs without metastasis and with metastasis
from primary image (A).
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FIGURE 5 | MSC treatment significantly reduces lung metastasis in
orthotopic xenograft model of Ewing’s sarcoma. MSC treated mice
compared to two control groups. Lung metastases are significantly fewer.
MSC, mice treated with mesenchymal stem cells weekly for 3 weeks;
CRL2300, lung epithelial cells, labeled the same as MSCs to serve as
control; PBS, phosphate buffered saline injected group to serve as a second
control group; LM, lung metastasis; CWT, chest wall tumor. Lung
metastasis significantly decreased in size *p=0.0178. (B) is a bar graph of
data displayed in (A).
cause any observed decrease in pulmonary metastasis as seen with
MSC therapy.
DISCUSSION
Preliminary research into the potential role of MSC therapy for ES
has shown promise; (8) however, at the time of this manuscript,
limited data has been published. Our ES model is unique in that
it allows for the study of both primary chest wall tumors as well
as pulmonary metastatic disease. MSCs have not previously been
used to treat ES lung metastasis. Our model exploits, what are
otherwise barriers, unique to the intravenous delivery of MSCs
and afford an opportunity to give insight into the potential role of
MSC therapy for ES metastasis. MSCs are known to sequester in
the lungs after intravenous delivery. Our data show that the intra-
venous injection of MSCs in an ES model decreases the volume
of pulmonary metastatic lesions. We found MSCs are found to
preferentially remain in the pulmonary parenchyma and remain
engrafted up to 5 days after delivery.
Fischer et al. have shown that the intravenous injection of MSCs
results in a significant first-pass pulmonary effect leading to the
majority of MSCs being sequestered within the lung parenchyma
(7). Additionally, Harting et al. have shown that as few as 1.5% of
MSCs bypass the pulmonary microvasculature after intravenous
injection (15). While such a high rate of pulmonary sequestra-
tion poses a barrier to systemic treatment, it poses a unique
opportunity for the treatment of the pulmonary metastatic dis-
ease associated with ES. Our data show that the majority of MSCs
remain within the lung parenchyma and a decrease in pulmonary
metastatic disease volume in MSC treated animals that is not
observed with a non-tumorigenic cell line (CRL2300). Primary
chest wall tumor size is not significantly affected by MSC ther-
apy and shows rebound growth. The rebound effect we saw in the
rib/chest wall tumors was very different than what we observed in
the lung metastasis. The reason for this is unknown. We speculate,
the differences in them microenvironment of the lung compared
to the chest wall, and the activity of immune modulators and
pro-inflammatory mediators, may affect these differences (16).
Since we are the first to show this effect of MSCs on lung malig-
nancies, we plan more research on the etiology. Other authors
have shown in carcinomas, MSCs can actually exacerbate tumor
growth; specifically in breast carcinomas (17, 18). However, in
gliomas, MSCs have been found to be therapeutic in reduction of
tumor growth (19). The major difference is sarcomas are from
mesenchymal origin and this may explain the potential thera-
peutic effect of MSCs on lung ES. Only one other group has
found MSCs to have antitumorigenic effect sarcoma, in Kaposi’s
sarcoma (20).
Mesenchymal stromal cells could be seen in the lung at 5 days
after the injection. Since the MSCs were delivered weekly, we don’t
know how long they would be present in the lung. In the future,
we anticipate isolating the patient’s own MSCs from their bone
marrow, and determining by Magnetic Resonance Imaging (MRI),
how long they remain in the lung. Sequential MRI exams could
also detect the effect of the MSCs in reduction or stabilization of
lung metastasis.
It was unexpected that the “naked” MSCs were able to sig-
nificantly decrease lung metastasis. This is the first time MSC
treatment has been demonstrated to reduce lung metastasis or any
other lung tumors. As a next step, we plan to transfect the MSCs
with ES specific targeted therapy to afford further reduction in
disease.
CONCLUSIONS
The intravenous injection of MSCs offers a novel potential therapy
for ES pulmonary metastasis. Our data show that the intravenous
injection of MSCs in an ES model decreases the volume of pul-
monary metastatic lesions. This is the first description of successful
MSC therapy of lung tumors.
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